HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Port-site metastasis after CO2 pneumoperitoneum: role of adhesion molecules and prevention with antiadhesion molecules.

AbstractBACKGROUND:
Port-site metastasis is a continuing problem in laparoscopic cancer surgery. To clarify the role of adhesion molecules in the development of port-site metastasis, particularly with regard to prevention, we performed experiments in which port-site metastasis was inhibited using antibodies against extracellular matrix proteins or the active Arg-Gly-Asp (RGD) peptide after CO2 pneumoperitoneum in a murine model.
METHODS:
We examined the development of port-site metastasis under the following conditions: (1) CO2 pneumoperitoneum with or without hyaluronic acid and anti-integrin or anti-CD44 antibody and (2) CO2 pneumoperitoneum and a RGD peptide or pseudo-RGD sequence peptide (FC-336). BALB/c mice ( n = 130) were injected with 5 x 10(5) human gastric cancer cells (MKN45) and either antibody or peptide, treated with CO2 pneumoperitoneum, and injected intraperitoneally with antibody or peptide for 5 days. Three weeks after CO2 pneumoperitoneum, the frequency and weight of port-site metastatic tumors were determined.
RESULTS:
Anti-integrin antibody significantly decreased the weight of port-site metastatic tumors without hyaluronic acid (control vs anti-integrin: 8.2 +/- 7.1 vs 3.6 +/- 4.5 mg; p < 0.05) but not the frequency of port-site metastases. With hyaluronic acid, the frequency of port-site metastasis and the weight of port-site metastatic tumors were significantly decreased both by anti-integrin and by anti-CD44 antibody (control vs anti-integrin and anti-CD44; 95% and 8.5 +/- 7.2 mg vs 50% and 3.1 +/- 4.3 mg and 55% and 3.3 +/- 5.1 mg, respectively; p < 0.05). RGD peptide and FC-336 also inhibited port-site metastasis in a dose-dependent manner.
CONCLUSION:
Cell adhesion molecules integrin and CD44 play an important role in the development of port-site metastasis after laparoscopic cancer surgery. Intraperitoneal injection of RGD peptide or pseudo-RGD sequence peptide (FC-336) can prevent port-site metastasis.
AuthorsY Hirabayashi, K Yamaguchi, N Shiraishi, Y Adachi, I Saiki, S Kitano
JournalSurgical endoscopy (Surg Endosc) Vol. 18 Issue 7 Pg. 1113-7 (Jul 2004) ISSN: 1432-2218 [Electronic] Germany
PMID15136928 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Cell Adhesion Molecules
  • FC 336
  • Hyaluronan Receptors
  • Integrins
  • Oligopeptides
  • Carbon Dioxide
  • arginyl-glycyl-aspartic acid
  • Hyaluronic Acid
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage, immunology, therapeutic use)
  • Antibody Specificity
  • Carbon Dioxide (administration & dosage)
  • Carcinoma (pathology)
  • Cell Adhesion Molecules (antagonists & inhibitors, physiology)
  • Cell Line, Tumor (transplantation)
  • Drug Evaluation, Preclinical
  • Drug Synergism
  • Female
  • Humans
  • Hyaluronan Receptors (immunology)
  • Hyaluronic Acid (administration & dosage, therapeutic use)
  • Injections, Intraperitoneal
  • Integrins (immunology)
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Seeding
  • Neoplasm Transplantation
  • Oligopeptides (administration & dosage, therapeutic use)
  • Pneumoperitoneum, Artificial (adverse effects)
  • Stomach Neoplasms (pathology)
  • Transplantation, Heterologous
  • Tumor Burden (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: